OTCMKTS:LXRP

Lexaria Bioscience (LXRP) Stock Price, News & Analysis

$0.22
-0.03 (-10.68%)
(As of 01/11/2021)
Today's Range
$0.21
$0.25
50-Day Range
$0.22
$0.22
52-Week Range
$0.17
$0.56
Volume
2.15 million shs
Average Volume
608,350 shs
Market Capitalization
$20.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
LXRP stock logo

About Lexaria Bioscience Stock (OTCMKTS:LXRP)

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

LXRP Stock Price History

LXRP Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Lexaria appoints Nelson Cabatuan as CFO
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
LEXX: GLP-1s’ Sweet Opportunity
Lexaria Announces 2023 Annual Meeting Results
See More Headlines
Receive LXRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Metal Mining
Sub-Industry
N/A
Current Symbol
OTCMKTS:LXRP
CUSIP
52886N208
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-4,090,000.00
Net Margins
-1,046.77%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$380,000.00
Book Value
$0.03 per share

Miscellaneous

Free Float
N/A
Market Cap
$20.15 million
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Christopher A. Bunka (Age 58)
    Chairman & CEO
    Comp: $300.8k
  • Mr. John M. Docherty (Age 51)
    Pres & Director
    Comp: $242.52k
  • Mr. Allan Spissinger C.A. (Age 51)
    CPA, CFO, Corp. Sec. & Treasurer
    Comp: $121.66k
  • Vanessa Carle
    Head of Legal
  • Dr. Philip Ainslie
    Advisor & Consultant

LXRP Stock Analysis - Frequently Asked Questions

How have LXRP shares performed in 2024?

Lexaria Bioscience's stock was trading at $0.2249 at the start of the year. Since then, LXRP stock has increased by 0.0% and is now trading at $0.2249.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Lexaria Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexaria Bioscience investors own include Aurora Cannabis (ACBFF), Organigram (OGI), Cronos Group (CRON), Aphria (APHQF), CV Sciences (CVSI), Auxly Cannabis Group (CBWTF), iAnthus Capital (ITHUF), Alibaba Group (BABA) and GW Pharmaceuticals (GWPH).

How do I buy shares of Lexaria Bioscience?

Shares of LXRP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:LXRP) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners